proteon manager software version 3 1 0 6 Search Results


bio rad proteon manager software  (Bio-Rad)
96
Bio-Rad bio rad proteon manager software
Bio Rad Proteon Manager Software, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bio rad proteon manager software/product/Bio-Rad
Average 96 stars, based on 1 article reviews
bio rad proteon manager software - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
proteon manager version 3.1.0.6  (Bio-Rad)
90
Bio-Rad proteon manager version 3.1.0.6
Proteon Manager Version 3.1.0.6, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteon manager version 3.1.0.6/product/Bio-Rad
Average 90 stars, based on 1 article reviews
proteon manager version 3.1.0.6 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
proteon manager version 3 1 0 6  (Bio-Rad)
93
Bio-Rad proteon manager version 3 1 0 6
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Proteon Manager Version 3 1 0 6, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteon manager version 3 1 0 6/product/Bio-Rad
Average 93 stars, based on 1 article reviews
proteon manager version 3 1 0 6 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) ProteOn array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.

Journal: Cancer immunology research

Article Title: Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA

doi: 10.1158/2326-6066.CIR-19-0023

Figure Lengend Snippet: (A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) ProteOn array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.

Article Snippet: For the assay, a HTG sensor chip (#1765031) and ProteOn Manager Version 3.1.0.6 (Bio-Rad Laboratories) were employed.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Recombinant, Negative Control, Control, Western Blot, Concentration Assay, Inhibition, Incubation, Comparison